Our Member Services Representatives are unavailable Friday, April 10, due to the holiday.

 

CORONAVIRUS (COVID-19)

Resources on COVID-19 and how BCBSND is responding to help protect all North Dakotans

Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia

Section: Surgery
Effective Date: July 01, 2018
Revised Date: November 12, 2019
Last Reviewed: November 14, 2019

Description

Hematopoietic Cell Transplantation
Hematopoietic cell transplantation (HCT) refers to a procedure in which hematopoietic cells are infused to restore bone marrow function in cancer patients who receive bone-marrow-toxic doses of cytotoxic drugs with or without whole body radiation therapy.

Conventional Preparative Conditioning for HCT
The conventional (classical) practice of allogeneic HCT involves administration of cytotoxic agents (e.g., cyclophosphamide, busulfan) with or without total body irradiation at doses sufficient to destroy endogenous hematopoietic capability in the recipient. The beneficial treatment effect in this procedure is due to a combination of initial eradication of malignant cells and subsequent graft-versus-malignancy (GVM) effect that develops after engraftment of allogeneic cells within the patient’s bone marrow space.

Reduced-Intensity Conditioning for Allogeneic HCT
Reduced-intensity conditioning (RIC) refers to the pretransplant use of lower doses or less intense regimens of cytotoxic drugs or radiation than are used in conventional full-dose myeloablative conditioning treatments.

Criteria

Allogeneic HCT using a myeloablative conditioning regimen may be considered medically necessary as a treatment of chronic myeloid leukemia (CML).

Allogeneic HCT using a RIC regimen may be considered medically necessary as a treatment of chronic myeloid leukemia in individuals who meet clinical criteria for an allogeneic HCT but who are not considered candidates for a myeloablative conditioning allogeneic HCT. These include those individuals whose age (typically greater than 60 years) or comorbidities (e.g., liver or kidney dysfunction, generalized debilitation, prior intensive chemotherapy, low Karnofsky Performance Status) preclude use of a standard myeloablative conditioning regimen.

Procedure Codes

38204 38205 38208 38209 38210 38211 38212
38213 38214 38215 38220 38221 38222 38230
38240 S2140 S2142

Autologous cell transplantation is considered experimental/investigational and, therefore, non-covered as a treatment of CML.

Although it remains a research interest, improved outcomes have not been demonstrated for autologous HCT compared with conventional chemotherapy in individuals with CML. At this time the role of autologous HCT for this indication has not been established.

Procedure Codes

38241

Autologous blood-derived hematopoietic progenitor cell harvesting and autologous bone marrow harvesting are considered experimental/investigational and, therefore, non-covered for autologous transplantation as a treatment of CML because the safety and/or effectiveness of this service cannot be established by the available published peer-reviewed literature.

Procedure Codes

38206 38232

Diagnosis Codes

Covered Diagnosis Codes for Procedure Codes 38204, 38205, 38208, 38209, 38210, 38211, 38212, 38213, 38214, 38215, 38220, 38221, 38222, 38230, 38240, S2140 and S2142 

C92.10 C92.12 C92.20 C92.22

 

Non-covered Diagnosis Codes for Procedure codes 38206, 38232, and 38241

C92.10 C92.12 C92.20 C92.22